The advantage of margetuximab over trastuzumab is its affinity (6.6 times greater) towards stimulatory CD16A FcγRIIIIA on N.K. cells and about 8.4 times less for the inhibitory CD32B FcγRIIB found on immune effector cells (N.K. cells and macrophages) within the innate immune system which improves the host’s immunological identification of cancer cells beyond trastuzumab (Kreutzfeldt et al. 2020). This evidence concerns the gene FCGR3A and cancer.